S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   271.54 (+2.39%)
AAPL   451.84 (+3.28%)
MSFT   208.65 (+2.59%)
FB   259.42 (+1.28%)
GOOGL   1,507.25 (+1.80%)
AMZN   3,160.57 (+2.59%)
NVDA   457.50 (+5.41%)
CGC   17.24 (+1.71%)
BABA   254.89 (+2.60%)
TSLA   1,557.10 (+13.29%)
GE   6.70 (-0.45%)
MU   48.40 (+1.34%)
AMD   82.69 (+7.56%)
T   30.17 (-0.10%)
F   7.10 (-1.80%)
ACB   9.80 (-2.20%)
GILD   68.71 (+0.90%)
NFLX   474.60 (+1.64%)
DIS   131.53 (+0.80%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   271.54 (+2.39%)
AAPL   451.84 (+3.28%)
MSFT   208.65 (+2.59%)
FB   259.42 (+1.28%)
GOOGL   1,507.25 (+1.80%)
AMZN   3,160.57 (+2.59%)
NVDA   457.50 (+5.41%)
CGC   17.24 (+1.71%)
BABA   254.89 (+2.60%)
TSLA   1,557.10 (+13.29%)
GE   6.70 (-0.45%)
MU   48.40 (+1.34%)
AMD   82.69 (+7.56%)
T   30.17 (-0.10%)
F   7.10 (-1.80%)
ACB   9.80 (-2.20%)
GILD   68.71 (+0.90%)
NFLX   474.60 (+1.64%)
DIS   131.53 (+0.80%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   271.54 (+2.39%)
AAPL   451.84 (+3.28%)
MSFT   208.65 (+2.59%)
FB   259.42 (+1.28%)
GOOGL   1,507.25 (+1.80%)
AMZN   3,160.57 (+2.59%)
NVDA   457.50 (+5.41%)
CGC   17.24 (+1.71%)
BABA   254.89 (+2.60%)
TSLA   1,557.10 (+13.29%)
GE   6.70 (-0.45%)
MU   48.40 (+1.34%)
AMD   82.69 (+7.56%)
T   30.17 (-0.10%)
F   7.10 (-1.80%)
ACB   9.80 (-2.20%)
GILD   68.71 (+0.90%)
NFLX   474.60 (+1.64%)
DIS   131.53 (+0.80%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   271.54 (+2.39%)
AAPL   451.84 (+3.28%)
MSFT   208.65 (+2.59%)
FB   259.42 (+1.28%)
GOOGL   1,507.25 (+1.80%)
AMZN   3,160.57 (+2.59%)
NVDA   457.50 (+5.41%)
CGC   17.24 (+1.71%)
BABA   254.89 (+2.60%)
TSLA   1,557.10 (+13.29%)
GE   6.70 (-0.45%)
MU   48.40 (+1.34%)
AMD   82.69 (+7.56%)
T   30.17 (-0.10%)
F   7.10 (-1.80%)
ACB   9.80 (-2.20%)
GILD   68.71 (+0.90%)
NFLX   474.60 (+1.64%)
DIS   131.53 (+0.80%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
Log in

NASDAQ:TROVTrovaGene Stock Price, Forecast & News

$5.97
-0.49 (-7.59 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.82
Now: $5.97
$6.57
50-Day Range
$3.19
MA: $4.77
$6.21
52-Week Range
$0.70
Now: $5.97
$3.46
Volume662,786 shs
Average Volume648,892 shs
Market Capitalization$65.74 million
P/E RatioN/A
Dividend YieldN/A
Beta1.04
Trovagene, Inc., a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. The PCM-075 is in Phase Ib/II clinical trial in acute myeloid leukemia (AML) and has completed a Phase I clinical trial in advanced solid tumors. The PCM-075 is also in preclinical studies with approximately 10 chemotherapeutic and target agents used in hematologic and solid tumor cancers, including Zytiga (abiraterone acetate); Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) in AML, metastatic castration-resistant prostate cancer and other hematologic and solid tumor cancers. Trovagene, Inc. primarily serves pharmaceutical companies and third party laboratories. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.
Read More
TrovaGene logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.28 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TROV
CUSIPN/A
Phone858-952-7570

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$250,000.00
Book Value$0.94 per share

Profitability

Net Income$-16,410,000.00
Net Margins-3,688.31%

Miscellaneous

EmployeesN/A
Market Cap$65.74 million
Next Earnings DateN/A
OptionableOptionable
$5.97
-0.49 (-7.59 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TROV News and Ratings via Email

Sign-up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











TrovaGene (NASDAQ:TROV) Frequently Asked Questions

How has TrovaGene's stock price been impacted by Coronavirus (COVID-19)?

TrovaGene's stock was trading at $1.11 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TROV stock has increased by 437.8% and is now trading at $5.97.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of TrovaGene?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TrovaGene in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for TrovaGene
.

How were TrovaGene's earnings last quarter?

TrovaGene Inc (NASDAQ:TROV) posted its quarterly earnings results on Thursday, February, 27th. The medical research company reported ($0.51) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.65) by $0.14. The medical research company earned $0.09 million during the quarter. TrovaGene had a negative return on equity of 202.00% and a negative net margin of 3,688.31%.
View TrovaGene's earnings history
.

When did TrovaGene's stock split? How did TrovaGene's stock split work?

TrovaGene shares reverse split before market open on Wednesday, February 20th 2019. The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 19th 2019. An investor that had 100 shares of TrovaGene stock prior to the reverse split would have 17 shares after the split.

What price target have analysts set for TROV?

2 analysts have issued twelve-month price objectives for TrovaGene's shares. Their forecasts range from $6.00 to $23.00. On average, they anticipate TrovaGene's share price to reach $14.50 in the next year. This suggests a possible upside of 142.9% from the stock's current price.
View analysts' price targets for TrovaGene
.

Has TrovaGene been receiving favorable news coverage?

News headlines about TROV stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. TrovaGene earned a news sentiment score of -2.2 on InfoTrie's scale. They also assigned news coverage about the medical research company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days.
View the latest news about TrovaGene
.

Are investors shorting TrovaGene?

TrovaGene saw a drop in short interest in the month of March. As of March 13th, there was short interest totaling 395,400 shares, a drop of 9.9% from the February 27th total of 438,900 shares. Based on an average trading volume of 200,100 shares, the short-interest ratio is presently 2.0 days.
View TrovaGene's Short Interest
.

Who are some of TrovaGene's key competitors?

What other stocks do shareholders of TrovaGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TrovaGene investors own include XOMA (XOMA), Inovio Pharmaceuticals (INO), Alnylam Pharmaceuticals (ALNY), Advanced Micro Devices (AMD), NVIDIA (NVDA), Alibaba Group (BABA), Opko Health (OPK), Cisco Systems (CSCO), Idera Pharmaceuticals (IDRA) and Novavax (NVAX).

Who are TrovaGene's key executives?

TrovaGene's management team includes the following people:
  • Dr. Thomas H. Adams, CEO & Exec. Chairman (Age 76)
  • Dr. Mark Erlander, Chief Scientific Officer (Age 59)
  • Ms. Elizabeth Anderson, VP of Fin. & Admin.
  • Mr. George Samuel, VP & Gen. Counsel
  • Ms. Vicki Kelemen, VP of Corp. Communications

What is TrovaGene's stock symbol?

TrovaGene trades on the NASDAQ under the ticker symbol "TROV."

How do I buy shares of TrovaGene?

Shares of TROV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TrovaGene's stock price today?

One share of TROV stock can currently be purchased for approximately $5.97.

How big of a company is TrovaGene?

TrovaGene has a market capitalization of $65.74 million and generates $250,000.00 in revenue each year. The medical research company earns $-16,410,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis.

What is TrovaGene's official website?

The official website for TrovaGene is www.trovagene.com.

How can I contact TrovaGene?

TrovaGene's mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The medical research company can be reached via phone at 858-952-7570 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.